When is ISO 8 Not ISO 8?

It is critically important that Users and Service Providers align on technical requirements for utilities prior to design, installation, and qualification.  Otherwise, a user may not get a system that fulfills their needs (User Requirements Specification).  

The International Organization for Standardization’s (ISO) standards are developed to ensure a common language/framework for users and service providers to agree on, and accept responsibilities for, the final quality of the system that is being requested/provided. So, if we simply categorize a need as ISO 8, which I will explain in a minute, the applicable standards vary, so facilities experts in the pharma industry need to be very specific about their requirements or they may end up with equipment (or a cleanroom) they cannot use.  

First, a bit of background. In the aseptic manufacturing spaces of the biopharmaceutical industry, ISO 8 is commonly meant to define the maximum non-viable particulate permitted per ISO 14644 (Cleanroom and Associated Controlled Environments standards), plus viable organism limits set by national regulatory authorities through FDA Guidance Documents [1] or European Union (EU) [2] rules.  In addition to the specific allowable limits, there also must be demonstrated control through appropriate engineering design of filtration, room air changes, differential pressures, etc.

ISO 8573 is the group of standards relating to the quality of compressed air. Interestingly, within this group of standards, ISO 8 also has a defined meaning. There are 10 listed purity classes which each define the maximum permissible amount of contamination allowed in a cubic meter of compressed air. Contaminants are defined as solid particulate, water, and oil, and each ISO purity class (0 – 9) permits an increasingly greater amount of contamination.

And now to the question that motivated me to write this article. As a user, if I specified that the compressed air entering my classified cleanroom was required to meet ISO 8 requirements, what standards/specifications would an engineer use to design a system that would fulfill my user requirement?

If the engineer was from a cleanroom design company, they would likely design the compressed air system to deliver air with the same quality as the specifications of the environment into which the air is introduced in compliance with ISO 14644-1:2015, i.e., not more than 3,520,000 particles ≥ 0.5µm per cubic meter, and based upon US / EU regulations not more than 100 CFU/m3 for an active air sample, and not more than 50 CFU/m3 for passive air sample (settle plates).  NOTE: CFU is Colony Forming Unit. They would also design the compressed air system to have particulate filtration, an extremely low amount of oil, and a moisture content that would preclude condensation from forming inside the delivery system.

If the engineer was from a company that built and sold compressed air and associated purifying equipment (dryers / coalescing filters / particulate filters), then the quality of the air would no doubt meet ISO 8573-1:2010, ISO 8 requirements, which are seen to be significantly different from 14644:2015 requirements. Particulate is allowed to be between 5 and ≤10 mg/m3, which indicates significantly more than 3,520,000 individual particles (≥ 0.5µm), moisture is allowed to be between 0.5 and ≤5 g/m3 (which could allow microbial growth), and oil content is allowed to be >5 mg/m3!  Clearly, air of this quality is not acceptable for use in pharmaceutical manufacturing.

When misunderstandings or misinterpretations of a specification occur, the results can be catastrophic. ISO 8 is not always the ISO 8 you thought it was, so make sure you are very, very precise in the questions you ask as you choose a vendor.

[1] Guidance for Industry - Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice, September 2004

[2] Eudralex The Rules Governing Medicinal Products in the European Union, Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use, Annex 1, Manufacture of Sterile Medicinal Products, August 2022


Bob Ferer, QxP Vice President, is a 30+-year veteran in pharma. Prior to joining QxP in 2012, Bob worked as an independent consultant. His roles have typically been facility and utility design/build projects, equipment procurement, qualification/validation, and facility start up. An engineering chemist by training, Bob supports QxP project teams from a compliance and regulatory aspect for the design, testing, qualification, and validation for facilities, critical utilities, maintenance, equipment, engineering, and manufacturing processes. Bob’s experience and insights have been very valuable to QxP clients.

Check out Bob’s two blogs about mistakes not to make when retrofitting facilities: Don’t Be a Daredevil When Retrofitting Your Facility, Part 1, and Don’t Be a Daredevil When Retrofitting Your Facility, Part 2.

The Crucial Nexus: Data Integrity in Pharmaceutical Manufacturing

Christine Feaster
May 17, 2024

Pharmaceutical Industry Trends for 2024 So Far

Christine Feaster
April 24, 2024

Decoding the Technical Transfer Process in Biotech Manufacturing

Sarah Boynton
April 23, 2024

Quality Executive Partners - IACET Accreditation

Ken Mead
April 9, 2024

Coaching and Correcting: A Focus on Behavior Over Blame

Sarah Boynton
November 1, 2023

The Importance of Roles and Responsibilities in Biotech Manufacturing & Human Error Prevention

Sarah Boynton
October 26, 2023

Remote cGMP Inspections and AI in Drug Manufacturing

Michelle Fishburne
October 11, 2023

4 Best Practices for Effective Investigation into Deviations

Sarah Boynton
September 19, 2023

The Art of Viral Vector Manufacturing: 4 Essential Controls to Prevent Cross-Contamination

Sarah Boynton
September 13, 2023

Practicing Risk Acceptance

Mark Roache
August 28, 2023

Annex 1 – Can we all take a deep breath now?

Vanessa Figueroa
August 24, 2023

In Cell and Gene, Good Science is Necessary, But Not Sufficient

Mark Roache
August 21, 2023

6 Ways To Achieve Manufacturing Audit And Inspection Readiness

Sarah Boynton
August 14, 2023

Experience is What You Get Just After You Needed It, Part 2

Mark Roache
August 10, 2023

Experience is What You Get Just After You Needed It, Part 1

Mark Roache
August 10, 2023

Sterility Assurance Matters to This ONE

Greg Gibb
August 8, 2023

Enhancing Quality and Safety: 3 Essential Human Error Prevention Tools for cGMP Manufacturing

Sarah Boynton
August 3, 2023

Asia-Pacific Happenings: Samsung Bioepis Implements QxP Virtuosi®

Michelle Fishburne
August 2, 2023

CDMOs – Selecting the Right One for Each Manufacturing Stage

Christine Feaster
July 24, 2023

3 Types of Human Error and Potential CAPAs to Prevent Them

Sarah Boynton
July 20, 2023

Drug Shortages: Causes & Solutions

Christine Feaster
July 10, 2023

The 5 Questions You Need to Ask After a Human Error Event Occurs

Sarah Boynton
July 5, 2023

Understanding How Adults Learn

Mike Levitt
June 30, 2023

Annex 1 and Ensuring Filling Technologies Fit the Need

Natasha Howard
June 21, 2023

How to Solve Pharma’s Skilled Workforce Deficit

Jeff Roy
June 20, 2023

ChatGPT Told Me AI is “Imperative” in Pharma Manufacturing

No items found.
June 18, 2023

Get Ready: FDORA’s Unannounced Foreign Inspection Pilot Program is On!

Crystal Mersh
June 6, 2023

Nitrosamines Impurity Challenges

Christine Feaster
June 2, 2023

All You Need to Know About Contamination Control Strategies, Parts 1 and 2

No items found.
June 1, 2023

Cost Of Quality: Worth Every Cent In Bio/Pharmaceutical Manufacturing

Crystal Mersh
May 24, 2023

Pharmaceutical Quality is NOT a Spectator Sport

Mike Levitt
May 22, 2023

The Six Keys for Effective Deviation Investigators

Mike Levitt
May 18, 2023

There Has to be a Better Way to Train

Tyler DeWitt, Ph.D.
May 15, 2023

Cell and Gene: Article Series on CGT’s Key Drivers

Mark Roache
May 8, 2023

Bacterial Endotoxin Testing is on the Move

Christine Feaster
May 5, 2023

Top 20 Pharma Company Chooses QxP Virtuosi® Platform

Vanessa Figueroa
May 3, 2023

Crystal Clear: Controls Are Not Enough

Crystal Mersh
April 22, 2023

Myth #1: Complying with Regulations and Product Specifications

Brian Duncan
April 20, 2023

Myth #2: Proactively Remediating Bad Inspection Outcomes: What’s the benefit?

Brian Duncan
April 20, 2023

Is it Time to Outsource Internal Auditing?

Mike Levitt
April 18, 2023

Quality is Number One, Even When Trying to Address Supply Chain Issues

Christine Feaster
April 14, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 2

Bob Ferer
April 10, 2023

Don’t Be a Daredevil When Retrofitting Your Facility, Part 1

Bob Ferer
April 10, 2023